MaaT’s FDA Woes Highlight Rocky Regulatory Path For Microbiome-Based Therapies
Clinical Hold Remains On Graft-Versus Host Disease Drug
Executive Summary
The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.